SAT0073 STAT3/STAT5 BALANCE AS A BIOMARKER IN RA: CTLA4-IG AND T CELL DIFFERENTIATION THROUGH STAT SIGNALING. (June 2019)

• Record Type: Journal Article
• Authors: Alivernini, Stefano; Tolusso, Barbara; Fedele, Anna Laura; Mario, Clara DI; Petricca, Luca; Gigante, Maria Rita; Ferraccioli, Gianfranco; Gremese, Elisa
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1100
• Page End: 1100
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.5749
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Regulatory T cells (Treg) play suppressive functions and are modulated by Abatacept (CTLA4-Ig). Limited data are available on CTLA4-Ig effect on Treg population in Rheumatoid Arthritis (RA). Objectives: The aim of the study was to analyze if STAT3/STAT5 expression in CD4+ T cells in peripheral blood (PB) of RA patients at baseline predicts response to Abatacept treatment (after 12 months follow-up). Methods: Early RA (ERA) and long-standing RA (LS-RA) patients with conventional DMARDs insufficient response were enrolled in this observational, investigative, monocentric, non-randomized, no profit study, and treated with CTLA4-Ig in combination with methotrexate. Each enrolled RA patients underwent peripheral blood sampling and CD4+ cells isolation using magnetic micro-beads at baseline and after 6-12 months follow-up. Flow cytometric analysis (FACS) for CD4 positive cells phenotype was performed to assess T-regulatory cells (Treg) as CD4+/CD25+/CD127- and CD4+/CD25+/Foxp3+, respectively. STAT3/STAT5 gene expression on CD4+ cells was performed by RT-PCR for each enrolled patient at every time-point follow-up. Low disease activity (LDA) and disease remission (DAS) achievement were assessed at 6 and 12 months follow-up (FU), respectively. Results: A total of 35 patients were enrolled in the study (16 ERA and 19 LS-RA, respectively). At baseline, ERA and LS-RA did not differ based on clinical parameters. Eight (22.9%) withdrew from the study because of treatment failure (n=6), severe infection (n=1) and death (n=1). LDA or DAS remission within twelve months follow-up were achieved in 28/34 (82.4%) and 16/34 (47.1%) patients, respectively, without any significant difference among ERA and LS-RA. There were no significant differences in the demographic and clinical characteristics of RA patients at study based on LDA or DAS remission status achievement within 12 months FU, even stratifying patients based on disease duration. FACS analysis showed CD4+/CD25+/CD127- and CD4+/CD25+/Foxp3+ cells decrease during CTLA4-Ig treatment (p=0.01 and p=0.02, respectively after 12 months FU), despite disease duration. RT-PCR revealed that PB CD4+ cells of RA patients achieving LDA, but not DAS remission, after CTLA4-Ig treatment have significantly lower endogenous expression of STAT3 and STAT5 compared to RA patients not achieving this outcome (p=0.03 and p<0.001, respectively). Moreover, baseline STAT3/STAT5 ratio in PB CD4+ cells of RA patients directly correlates with Treg cells percentages (CD4+/CD25+/CD127- cells (%): R=0.518, p=0.03; CD4+/CD25+/Foxp3+ cells (%): R=0.549, p=0.02, respectively). Finally, baseline STAT3/STAT5 expression ratio on CD4+ cells > 0.93 (obtained by ROC analysis: AUC:0.754+/-0.100; Sensitivity 75.0%, Specificity: 80.0%) arose as baseline predictor factor of LDA achievement in RA patients treated with CTLA4-Ig [OR(95%CIs): 12.0 (1.98-72.89)]. Conclusion: STAT3/STAT5 expression ratio in T cells at baseline identify RA patients better responding to CTLA4-Ig, which decreases Treg cells. Disclosure of Interests: Stefano Alivernini Speakers bureau: BMS, Barbara Tolusso: None declared, Anna Laura Fedele: None declared, Clara Di Mario: None declared, Luca Petricca: None declared, Maria Rita Gigante: None declared, Gianfranco Ferraccioli Speakers bureau: BMS, Roche, Elisa Gremese Consultant for: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Speakers bureau: BMS, Speakers bureau: Roche, Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer